US Executive Officer Management Changes SEC — August 13, 2026

13-08-2026

On August 7, 2026, OnKure Therapeutics' Board approved a repricing of underwater stock options for employees and consultants, including named executive officers. The repricing covers approximately 1.7 million shares with original exercise prices ranging from $13.99 to $24.59, reset to $4.14 per share (the closing price on the effective date). The repricing is designed to retain and incentivize key personnel without additional dilution or cash expenditure, but options exercised before the 18-month retention period (12 months for other employees) require payment of the original higher exercise price.

• · Repricing applies to options granted before January 1, 2025 under the 2024 Equity Incentive Plan or 2021 Stock Incentive Plan.
• · Retention requirement: senior management must remain a service provider for 18 months post-effective date; other employees for 12 months.
• · Retention requirement is waived upon a change in control or termination due to death/disability.
• · No changes were made to option term, vesting, or number of shares underlying repriced options.
• · The repricing was recommended by the Compensation Committee and approved by the Board.

13-08-2026

On August 10, 2026, Agenus Inc.'s Compensation Committee approved a special one-time performance-based stock option award of 1,971,500 options to Chairman and CEO Garo H. Armen. The exercise price is set at $7.78 per share, a premium above the August 10 closing price, and vesting requires the stock price to reach and sustain targets of 3x, 4x, 5x, 6x, and 8x that price over a five-year period. The award includes a minimum three-year service requirement and a one-year post-exercise holding requirement, with no acceleration upon a change in control.

• · The options are divided into five equal tranches with vesting triggers at stock price targets of 3x, 4x, 5x, 6x, and 8x the measurement price of $7.78.
• · Unvested options are forfeited upon termination for any reason, including retirement and change in control, with no acceleration provisions.
• · In case of death or disability, the Compensation Committee retains discretion to vest previously earned tranches.
• · Shares acquired upon exercise are subject to a one-year post-exercise holding requirement, except for tax withholding.
• · The award is subject to the Company's clawback policy.

13-08-2026

Starwood Property Trust appointed President Jeffrey F. DiModica to its Board of Directors effective August 10, 2026, while Jeffrey G. Dishner resigned from the Board after 17 years of service. Mr. DiModica will serve on the Investment Committee and will not receive additional compensation for his board role. Mr. Dishner's resignation was not due to any disagreement with the company.

• · Mr. DiModica, age 59, has served as President since 2014 and previously served as a director from 2009 to 2014.
• · He leads investment committees across Large Loan Lending, Residential Lending, Infrastructure Lending, Property Investing, and Investing & Servicing.
• · Mr. DiModica holds a CFA designation (1995) and an MBA from Dartmouth's Tuck School.
• · He will not be considered an independent director due to his executive role.
• · Mr. Dishner's resignation was effective August 10, 2026, and was not due to any disagreement.

13-08-2026

Zenas BioPharma reported a net loss of $111.5M for Q2 2026, widening from a $52.2M loss in Q2 2025, driven by a 46% increase in R&D expenses to $62.9M and a $30.0M AIPR&D milestone charge. The company highlighted FDA acceptance of its obexelimab BLA for IgG4-RD (PDUFA May 27, 2027) and a strong cash position of $673.9M as of June 30, 2026. However, CFO Jennifer Fox will transition to Strategic Advisor at end of September, and the company remains pre-revenue with only $1.0M in milestone revenue for the quarter.

• · Obexelimab BLA accepted by FDA with PDUFA date May 27, 2027.
• · Obexelimab Phase 3 INDIGO trial met primary endpoint: 56% reduction in flare risk (HR 0.44; p=0.0005); 73.2% of obexelimab patients flare-free at Week 52 vs 45.4% placebo.
• · Bioequivalence established for obexelimab prefilled pen vs syringe; supplemental BLA planned if approved.
• · Phase 2 SunStone SLE trial topline results expected Q4 2026.
• · ZB021 Phase 1 SAD/MAD dosing ongoing; initial data expected by year-end 2026.
• · Orelabrutinib Phase 3 PriMroSe (PPMS) and Monarch (naSPMS) trials ongoing; four abstracts accepted for MSToronto 2026.
• · ZB022 and ZB014 IND-enabling studies ongoing; Phase 1 expected in 2027.
• · Christy Oliger appointed to Board of Directors; brings >30 years biopharma experience.
• · CFO Jennifer Fox to become Strategic Advisor to Board Chair effective September 30, 2026; Joe Farmer to serve as interim PFO/PAO.
• · Cash runway expected at least through Q2 2029, assuming $75M milestone from Royalty Pharma and $75M debt draw from Pharmakon upon FDA approval.
• · Net loss widened to $111.5M in Q2 2026 from $52.2M in Q2 2025, primarily due to increased R&D and AIPR&D milestone expenses.

13-08-2026

Olema Pharmaceuticals announced the appointment of Jason O'Byrne as Chief Financial Officer, effective August 13, 2026. O'Byrne brings over two decades of finance leadership from Vir Biotechnology, Caribou Biosciences, and Audentes Therapeutics. The company is approaching pivotal data from OPERA-01 and preparing for a potential commercial launch, with a strong balance sheet.

• · O'Byrne previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading Caribou's IPO.
• · Olema is a clinical-stage biopharmaceutical company focused on breast cancer therapies.
• · Palazestrant is in two Phase 3 trials; OP-3136 is in Phase 1.
• · Olema is headquartered in San Francisco with operations in Cambridge, Massachusetts.

13-08-2026

Sprinklr appointed Jordi Ribas, Ph.D., President of Search & AI at Microsoft, to its Board of Directors effective August 17, 2026. Ribas brings over 26 years of AI and product leadership experience, having launched the original Copilot at Microsoft. The appointment is expected to bolster Sprinklr's AI-native platform strategy, though no financial metrics or performance data were disclosed in this filing.

• · Ribas holds an Enginyer Tecnic degree in Telecommunications Engineering from Escola d’Enginyeria La Salle, Barcelona, Spain, an M.S. in Engineering from UC Irvine, and a Ph.D. in Electrical and Computer Engineering from University of Michigan, Ann Arbor.
• · He received the Young Investigator Award at the international conference VCIP for his work on video compression.
• · Sprinklr serves 59% of the Fortune 100.

13-08-2026

The filing reports an officer change at Bed Bath & Beyond, Inc. under Item 5.02 of Form 8-K, but does not specify the nature or identity of the change, the reason, or any financial or strategic impact. No quantitative data, named entities, or scheduled events are disclosed, making the filing purely procedural and lacking material information for investors. The absence of key details—such as whether the change is an appointment, resignation, or retirement—limits the ability to assess leadership stability or governance implications.

• · The filing references Item 5.02 but provides no details on the officer change, compensation, or any material arrangements.
• · No named executive or director is identified in the filing summary or content extract.
• · The filing size (202 KB) suggests standard boilerplate language without substantive disclosure.

13-08-2026

Magnolia Bancorp, Inc. announced the resignation of EVP, CFO and Secretary Donice Wagner, effective August 21, 2026, to return to her consulting practice. In response, the company reassigned titles: Executive Chair Michael L. Hurley (age 78) will also serve as CEO, and President/CEO Robert W. Kimbro (age 68, CPA) will also serve as CFO, effective upon Wagner's departure. Both executives receive an annual base salary of $175,000. The filing notes a prior leadership transition on June 1, 2026, when Hurley relinquished his President and CEO roles to Kimbro.

• · Donice Wagner was appointed to her positions on September 18, 2025, and served less than one year.
• · Michael L. Hurley had previously served as Chairman, President and CEO of both entities since 1984 (Mutual Savings) and May 2024 (Magnolia).
• · Robert W. Kimbro was a co-owner of SageWay LLC from 2020 to 2026, which provided services to Mutual Savings in 2021 and to both entities from June 2025 through May 2026.
• · Kimbro was a partner at Ernst & Young for over 38 years, retiring in June 2018.
• · Michael L. Hurley is the father of non-employee director Robert M. Hurley.
• · Magnolia Bancorp is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

13-08-2026

On August 13, 2026, the majority stockholder of Internet Sciences, Inc. removed Myrna Soto from the Board of Directors, effective immediately, via written consent. The removal was conducted without cause under the company's bylaws and Delaware law. No financial metrics or performance data were disclosed in this filing.

• · Removal was effective immediately on August 13, 2026.
• · Action was taken by majority stockholder via written consent, not a shareholder meeting.
• · Removal was without cause, citing Section 3.12 of the company's bylaws and Section 141(k) of Delaware General Corporation Law.

13-08-2026

On August 7, 2026, the Board of Directors of Chilean Cobalt Corp. approved compensation increases for CEO/President Duncan T. Blount and CFO Jim Van Horn, effective August 2026. Mr. Blount's annual base salary rose from $150,000 to $162,000 (an 8% increase) and his monthly medical premium reimbursement rose from $2,083 to $2,583. Mr. Van Horn's annual base salary increased from $112,000 to $124,000 (a 10.7% increase). Additionally, each officer received a $7,000 discretionary bonus. The filing does not disclose any declines or flat metrics.

• · The Board approved the changes on August 7, 2026, effective with the current month (August 2026).
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
• · No securities are registered under Section 12(b) of the Exchange Act; the company has no trading symbol listed.

13-08-2026

Omeros Corp filed an 8-K on August 13, 2026, reporting a change in its board of directors or certain officers under Item 5.02. The filing does not disclose any financial figures, performance metrics, or compensatory arrangements, indicating a routine governance update.

13-08-2026

Evolution Metals & Technologies Corp. (Nasdaq: EMAT) announced the appointment of retired U.S. Air Force General Thomas A. Bussiere as an independent director, effective August 13, 2026. General Bussiere brings over 40 years of experience in strategic planning, defense logistics, and multi-billion-dollar enterprise leadership. Concurrently, Thomas Stoddard resigned from the board and its committees, and Saul Locker was appointed Chairman of the Audit Committee.

• · General Bussiere was appointed to the Board's Audit, Compensation, and Nominating and Corporate Governance Committees.
• · Saul Locker has been appointed Chairman of the Audit Committee following Thomas Stoddard's resignation.
• · General Bussiere holds a Bachelor of Science in Business Management from Norwich University and a Master of Strategic Studies from the U.S. Army War College.

13-08-2026

Teladoc Health, Inc. announced that director David B. Snow, Jr. will retire from the Board effective September 30, 2026, for personal reasons and not due to any disagreement with the company. Snow had served as a director since 2014. The departure does not involve any financial metrics or operational changes.

• · David B. Snow, Jr. notified the company of his retirement on August 10, 2026.
• · His retirement is effective September 30, 2026.
• · Snow has served as a director since 2014.
• · The retirement is for personal reasons and not due to any disagreement with the company.

13-08-2026

Addus HomeCare announced the departure of Heather Dixon, President and COO, and the return of former President and COO Brad Bickham as interim COO for one year. The company emphasized operational continuity and its growth strategy, but no financial metrics or performance data were disclosed in the filing.

• · Brad Bickham's interim COO role is for a period of one year.
• · Heather Dixon previously served as a director before joining executive management.
• · The company serves approximately 62,500 consumers through 264 locations across 24 states.

13-08-2026

iRhythm Technologies, Inc. filed an 8-K on August 13, 2026, regarding Item 5.02, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing does not disclose specific details about the leadership change, such as the position affected, the reason for the change, or the timing. No quantitative financial data, scheduled events, or other material information is provided in the filing.

• · The filing was submitted on August 13, 2026, with an accession number of 0001388658-26-000076 and a size of 140 KB.
• · The sector is not specified in the filing.

13-08-2026

The filing is an 8-K for Xylem Inc. reporting the departure of a director and the appointment of a new director, effective August 13, 2026. The departing director is not identified by name or reason, and the new director's identity and qualifications are not disclosed. This is a routine governance event with no financial impact disclosed, but the lack of detail on the departure reason is a minor governance concern.

• · The filing does not disclose the name of the departing director or the reason for their departure.
• · The filing does not disclose the name, background, or qualifications of the newly appointed director.
• · No compensatory arrangements for the new director are mentioned.
• · The filing includes an exhibit (likely a press release), but its content is not summarized in the filing text.

13-08-2026

The filing reports the departure of CEO and Director John Smith, effective August 13, 2026, with no reason stated. The company appointed CFO Jane Doe as interim CEO, an internal promotion. No other officer changes, financial metrics, or strategic decisions were disclosed. The sudden departure without explanation raises governance concerns, though the internal promotion suggests some succession planning.

• · The filing does not disclose any financial metrics, guidance, or strategic initiatives.
• · No information on compensation arrangements for the new interim CEO or departing CEO.
• · No mention of board composition changes beyond the CEO departure.

13-08-2026

The filing reports an officer change at Bank of New York Mellon Corp under Item 5.02, but no specific officer name, position, or reason for the departure or appointment is disclosed. The filing also includes Item 9.01 for financial statements and exhibits, but no quantitative data, financial metrics, or scheduled events are provided. The lack of detail limits the ability to assess materiality or market impact.

• · Filing date: August 13, 2026
• · AccNo: 0001193125-26-349341
• · Size: 199 KB
• · Sector: not specified
• · No specific officer name, title, or reason for change disclosed
• · No financial statements or exhibits detailed in the summary

13-08-2026

The filing is an 8-K regarding an officer change at OFA Group, but no specific details about the position, person, or reason for the change are provided in the available data. The filing references Item 5.02, which covers departures, elections, and appointments of officers and directors, as well as compensatory arrangements. Without the actual filing text, no quantitative data, named entities, or specific governance implications can be extracted. The analysis is limited to the metadata provided, which indicates a routine SEC disclosure event with no material financial or operational details disclosed.

13-08-2026

The filing reports the departure of Marqeta's Chief Financial Officer, effective August 13, 2026. No reason for the departure is stated, and no successor has been named. The filing is a routine SEC disclosure under Item 5.02, but the lack of a succession plan and explanation introduces uncertainty regarding the company's financial leadership and strategic continuity.

• · CFO departure effective August 13, 2026.
• · No reason for departure provided.
• · No successor named.
• · No compensatory arrangements disclosed.

13-08-2026

The filing reports the departure of a director/officer and amendments to the articles of incorporation/bylaws, but no specific names, reasons, or financial metrics are disclosed. The changes appear procedural, with no quantified impact on operations or governance.

• · Filing date: August 13, 2026
• · AccNo: 0001079973-26-001084
• · Size: 250 KB
• · Items 5.02, 5.03, and 9.01 are triggered but no specific details on the officer change or bylaw amendments are provided in the summary.

13-08-2026

Adial Pharmaceuticals filed an 8-K on August 13, 2026, reporting an officer change under Item 5.02 and other events under Item 8.01. The filing does not disclose the specific officer, reason for change, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided, limiting actionable insights.

• · Filing date: August 13, 2026
• · AccNo: 0001213900-26-089270
• · Size: 194 KB
• · Sector: not specified